Skip to content

Interactive Multirisk-Factor Intervention for Hypertension (HTN) Blacks

Interactive Multirisk-Factor Intervention for HTN Blacks

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00207194
Enrollment
337
Registered
2005-09-21
Start date
2001-10-31
Completion date
2007-08-31
Last updated
2016-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

The aim of this study is to assess the efficacy of Telephone-Linked\_Care for Hypertension Regimen Adherence in an African American population (TLC-HTN-AA). TLC-HTN-AA is a computer-based telecommunication system that will monitor, educate and counsel African American adults with hypertension on adherence to medication, diet, and exercise. The primary hypotheses are: 1. TLC-HTN-AA use will improve medication regiment adherence 2. TLC-HTN-AA will improve adherence to 3 healthy diet recommendations 3. TLC-HTN-AA will improve levels of regular exercise 4. Patients receiving TLC-HTN-AA will be more likely to become adherent to all 3 target regiments than patients in the control group

Interventions

BEHAVIORALAutomated Telephone Program

The intervention incorporated principles of social cognitive theory, the transtheoretical model of behavioral change, and motivational interviewing, and was tailored to the user's values. Content was also adapted to cultural characteristics of culturally African-American adults (i.e., not Caribbean-American, Black-Hispanic, etc.). These participants also received the same health behavior education those in the control condition received.

BEHAVIORALHealth Behavior Education

Participants received a 75-page resource manual that described hypertension, listed dietary recommendations, heart healthy food recipes, and local resources for exercise, and provided information to support antihypertensive medication adherence. They received a 20-min education session based on the content of this manual, and were given a pedometer and a digital weight scale (Healthometer, model # HDR900KD01).

Sponsors

Boston Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
35 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* a patient with a primary care provider at one of Boston Medical Center's Adult Primary Care Medical Practices or one of three HealthNet health centers participating in the study * have a physician diagnosis of hypertension * be African American by self-report * be 35 years of age or older * be prescribed at least one medication for hypertension * have poorly controlled blood pressure * be non-adherent to at least one hypertensive medication * understand spoken English * have a home telephone

Exclusion criteria

* patients for whom a medication, diet or exercise regiment adherence improvement or maintenance program would be inappropriate * patients with a terminal illness * patients with severe medical or psychiatric illness * patients with cognitive difficulty

Design outcomes

Primary

MeasureTime frameDescription
1-proportion of study subjects who achieve adequate adherence (greater than or equal to 80% of doses taken) at the end of the intervention period8 monthsOutcomes were assessed at baseline, 4 months, 8 months (the end of the study intervention) and 12 months.
2-consumption of more than 5 servings of fruits and vegetables a day, less than 30% of calories from fat, and less than 2400 mg of sodium a day at the end of the intervention period8 monthsOutcomes were assessed at baseline, 4 months, 8 months (the end of the study intervention) and 12 months.
3-adherence to CDC-ACSM recommendations for moderate intensity physical activity at the end of the intervention period8 monthsOutcomes were assessed at baseline, 4 months, 8 months (the end of the study intervention) and 12 months.

Secondary

MeasureTime frameDescription
1-TLC-HTN-AA use will reduce the mean blood pressure and the proportion of the treatment group having uncontrolled hypertension at the end of the intervention period8 monthsOutcomes were assessed at baseline, 4 months, 8 months (the end of the study intervention) and 12 months.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026